SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) July 23, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On July 18, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that a 510(k) Notification has been
submitted to the Food and Drug Administration (FDA) by
HemoCleanse, Inc., which works in conjunction with BICO
subsidiary, IDT, Inc. The 510(k) requests market clearance for
the ThermoChem HT System (ThermoChem) for use in Intraperitoneal
Hyperthermic Chemotherapy (IPHC). The ThermoChem HT System was
formerly known as the BioLogic-HTA, a part of the BioLogic-HT
System, currently being tested by IDT, Inc., in conjunction
with HemoCleanse, Inc., for whole-body extracorporeal hyperthermia
treatment of cancer and HIV/AIDS.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: July 23, 1997
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
510(K) SUBMITTED TO FDA ON PRODUCT TO BE MARKETED BY BIOCONTROL
SUBSIDIARY, IDT
Pittsburgh, PA - July 23, 1997 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that a 510(k) Notification has been
submitted to the Food and Drug Administration (FDA) by
HemoCleanse, Inc., which works in conjunction with BICO
subsidiary, IDT, Inc. The 510(k) requests market clearance for
the ThermoChem HT System (ThermoChem) for use in Intraperitoneal
Hyperthermic Chemotherapy (IPHC).
HemoCleanse, Inc., of West Lafayette, IN, manufactures the
ThermoChem while IDT holds exclusive worldwide marketing rights
to the ThermoChem and related disposables.
The ThermoChem HT System was formerly known as the BioLogic-
HTA, a part of the BioLogic-HT System, currently being tested
by IDT, Inc., in conjunction with HemoCleanse, Inc., for whole-
body extracorporeal hyperthermia treatment of cancer and
HIV/AIDS. The product name was changed to provide clear product
identification in the intended market.
The ThermoChem HT System heats and/or cools fluids, such as
chemotherapy agents in solution, and recirculates these fluids
into the peritoneal (abdominal) cavity, thus providing a
hyperthermic condition for combined cancer therapy.
ThermoChem and related disposables are intended to be used
in a hospital operating room and in ambulatory settings for
patients with gastrointestinal and other cancers within the
peritoneal cavity.
Biocontrol Technology, Inc. has its corporate offices
in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
IDT, Inc., a wholly-owned subsidiary of Biocontrol also located
in Pittsburgh, PA, holds exclusive worldwide marketing rights to
the ThermoChem HT System, which is manufactured by HemoCleanse
